SEARCH VEGSOURCE:

 

 

Follow Ups | Post Followup | Back to Discussion Board | VegSource
See spam or
inappropriate posts?
Please let us know.
  




From: TSS ()
Subject: Monthly CJD statistics Definite UK 8/1/05
Date: August 2, 2005 at 7:05 am PST

CJD WATCH MESSAGE BOARD
TSS
Monthly CJD statistics Definite UK 8/1/05
Mon Aug 1, 2005 16:00
68.238.106.127

Monthly Creutzfeldt Jakob disease statistics
Published:
Monday 1 August 2005
Reference number:
2005/0277

The Department of Health is today issuing the latest information about the numbers of known cases of Creutzfeldt Jakob disease. This includes cases of variant Creutzfeldt Jakob disease (vCJD) - the form of the disease thought to be linked to BSE. The position is as follows:

Definite and probable CJD cases in the UK: 1st of August

Summary of vCJD cases

Deaths

Deaths from definite vCJD (confirmed): 107

Deaths from probable vCJD (without neuropathological confirmation): 42

Deaths from probable vCJD (neuropathological confirmation pending): 1

Number of deaths from definite or probable vCJD (as above): 150

Alive

Number of probable vCJD cases still alive: 7

Total number of definite or probable vCJD (dead and alive): 157

The next table will be published on Monday 1st of September 2005

Referrals: a simple count of all the cases which have been referred to the National CJD Surveillance Unit for further investigation in the year in question. CJD may be no more than suspected; about half the cases referred in the past have turned out not to be CJD. Cases are notified to the Unit from a variety of sources including neurologists, neuropathologists, neurophysiologists, general physicians, psychiatrists, electroencephalogram (EEG) departments etc. As a safety net, death certificates coded under the specific rubrics 046.1 and 331.9 in the 9th ICD Revisions are obtained from the Office for National Statistics in England and Wales, the General Register Office for Scotland and the General Register Office for Northern Ireland.

Deaths: All columns show the number of deaths that have occurred in definite and probable cases of all types of CJD and GSS in the year shown. The figures include both cases referred to the Unit for investigation while the patient was still alive and those where CJD was only discovered post mortem (including a few cases picked up by the Unit from death certificates). There is therefore no read across from these columns to the referrals column. The figures will be subject to retrospective adjustment as diagnoses are confirmed.

Definite cases: this refers to the diagnostic status of cases. In definite cases the diagnosis will have been pathologically confirmed, in most cases by post mortem examination of brain tissue (rarely it may be possible to establish a definite diagnosis by brain biopsy while the patient is still alive).

Probable vCJD cases: are those who fulfil the 'probable' criteria set out in the Annex and are either still alive, or have died and await post mortem pathological confirmation. Those still alive will always be shown within the current year's figures.

Sporadic: Classic CJD cases with typical EEG and brain pathology. Sporadic cases appear to occur spontaneously with no identifiable cause and account for 85% of all cases.

Probable sporadic: Cases with a history of rapidly progressive dementia, typical EEG and at least two of the following clinical features; myoclonus, visual or cerebellar signs, pyramidal/extrapyramidalsigns or akinetic mutism.

Iatrogenic: where infection with classic CJD has occurred accidentally as the result of a medical procedure. All UK cases have resulted from treatment with human derived pituitary growth hormones or from grafts using dura mater (a membrane lining the skull).

Familial: cases occurring in families associated with mutations in the PrP gene (10 - 15% of cases).

GSS: Gerstmann-Straussler-Scheinker syndrome - an exceedingly rare inherited autosomal dominant disease, typified by chronic progressive ataxia and terminal dementia. The clinical duration is from 2 to 10 years, much longer than for CJD.

vCJD: Variant CJD, the hitherto unrecognised variant of CJD discovered by the National CJD Surveillance Unit and reported in The Lancet on 6 April 1996. This is characterised clinically by a progressive neuropsychiatric disorder leading to ataxia, dementia and myoclonus (or chorea) without the typical EEG appearance of CJD. Neuropathology shows marked spongiform change and extensive florid plaques throughout the brain.

Definite vCJD cases still alive: These will be cases where the diagnosis has been pathologically confirmed (by brain biopsy).

Related links
Download CJD Statistics 01/08/2005 (PDF, 12K)
Notes to editor
ANNEX

DIAGNOSTIC CRITERIA FOR VARIANT CJD

I A) PROGRESSIVE NEUROPSYCHIATRIC DISORDER

B) DURATION OF ILLNESS > 6 MONTHS

C) ROUTINE INVESTIGATIONS DO NOT SUGGEST AN ALTERNATIVE

DIAGNOSIS

D) NO HISTORY OF POTENTIAL IATROGENIC EXPOSURE

II A) EARLY PSYCHIATRIC SYMPTOMS *

B) PERSISTENT PAINFUL SENSORY SYMPTOMS **

C) ATAXIA

D) MYOCLONUS OR CHOREA OR DYSTONIA

E) DEMENTIA

III A) EEG DOES NOT SHOW THE TYPICAL APPEARANCE OF SPORADIC

CJD *** (OR NO EEG PERFORMED)

B) BILATERAL PULVINAR HIGH SIGNAL ON MRI SCAN

IV A) POSITIVE TONSIL BIOPSY

DEFINITE: IA (PROGRESSIVE NEUROPSYCHIATRIC DISORDER) and

NEUROPATHOLOGICAL CONFIRMATION OF vCJD ****

PROBABLE: I and 4/5 OF II and III A and III B

or I and IV A

* depression, anxiety, apathy, withdrawal, delusions.

** this includes both frank pain and/ or unpleasant dysaesthesia

*** generalised triphasic periodic complexes at approximately one per second

****spongiform change and extensive PrP deposition with florid plaques, throughout the cerebrum and cerebellum.

http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT_ID=4116952&chk=4bnS%2Bp

CREUTZFELDT-JAKOB DISEASE IN THE UK

By Calendar Year

REFERRALS OF

SUSPECT CJD

DEATHS OF DEFINITE AND PROBABLE CJD

Year Referrals Year Sporadic Iatrogenic Familial GSS vCJD Total

Deaths

1990 [53] 1990 28 5 0 0 - 33

1991 75 1991 32 1 3 0 - 36

1992 96 1992 45 2 5 1 - 53

1993 78 1993 37 4 3 2 - 46

1994 118 1994 53 1 4 3 - 61

1995 87 1995 35 4 2 3 3 47

1996 133 1996 40 4 2 4 10 60

1997 162 1997 60 6 4 1 10 81

1998 154 1998 63 3 3 2 18 89

1999 170 1999 62 6 2 0 15 85

2000 178 2000 50 1 2 1 28 82

2001 179 2001 58 4 3 2 20 87

2002 163 2002 72 0 4 1 17 94

2003 162 2003 77 5 4 2 18 106

2004 114 2004 52 2 3 1 9 67

2005* 74 2005 24 1 1 1 2 29

Total

Referrals 1996 Total

Deaths 788 49 45 24 150 1056

* As at 29 July 2005

Summary of vCJD cases

Deaths

Deaths from definite vCJD (confirmed): 107

Deaths from probable vCJD (without neuropathological confirmation): 42

Deaths from probable vCJD (neuropathological confirmation pending): 1

Number of deaths from definite or probable vCJD (as above): 150

Alive

Number of definite/probable vCJD cases still alive: 7

Total number of definite or probable vCJD (dead and alive): 157

http://www.dh.gov.uk/assetRoot/04/11/69/51/04116951.pdf

TSS


CJD (NEW VARIANT) UPDATE 2005 (08)
*********************************
A ProMED-mail post

ProMED-mail is a program of the
International Society for Infectious Diseases

Sponsored in part by Elsevier, publisher of
Transactions of the Royal Society of Tropical Medicine and Hygiene

[The UK Department of Health web-site has been
revised, and the monthly new variant
Creutzfeldt-Jakob disease statistics are now
appended to the table "Creutzfeldt-Jakob disease
in the UK by Calendar Year (since 1990)," which
can be accessed at
.
The definition of the designations deaths,
definite cases, probable vCJD cases, and, the
case definitions can be found by accessing the
Department of Health web-site, or, by reference
to a previous ProMED-mail post in this thread
(for example, CJD (new var.) - UK: update Mar
2002 20020305.3693).

The incidence of variant Creutzfeldt-Jakob
disease, abbreviated CJD (new var.) or vCJD in
ProMED-mail, in the UK appears to have reached a
plateau, or perhaps to be in decline. Therefore,
since many of the reports appearing in the update
are only peripherally related to the situation in
the UK, the opportunity is being taken to drop
the designation UK from the title of this thread.

Also, data on other forms of CJD (sporadic,
iatrogenic, familial and GSS) are now included
when they have some relevance to the incidence
and etiology of vCJD. - Mod.CP]

In this update:

[1] UK: DH vCJD monthly statistics - as of Mon 1 Aug 2005
[2] & [3] UK - warning to blood donors
[4] & [5] Spain - 1st (suspected) vCJD case

******
[1] UK: DH vCJD monthly statistics - as of Mon 1 Aug 2005
Date: Mon 1 Aug 2005
From: ProMED-mail
Source: UK Department of Health, Monthly
Creutzfeldt-Jakob Disease Statistics, Press
release no. 2005/0277, Mon 1 Aug 2005 [edited]


Monthly Creutzfeldt Jakob Disease Statistics - As of 1 Aug 2005
-----------------------------------------------
The Department of Health is today [Mon 1 Aug
2005] issuing the latest information about the
numbers of known cases of Creutzfeldt Jakob
disease. This includes cases of variant
Creutzfeldt Jakob disease [abbreviated in
ProMED-mail as CJD (new var.) or vCJD], the form
of the disease thought to be linked to BSE. The
position is as follows:

Definite and probable CJD cases in the UK:

Summary of vCJD Cases - Deaths
-----------------------------

Deaths from definite vCJD (confirmed): 107

Deaths from probable vCJD (without neuropathological confirmation): 42

Deaths from probable vCJD (neuropathological confirmation pending): 1

Number of deaths from definite or probable vCJD (as above): 150

Summary of vCJD Cases - Alive
-----------------------------

Number of probable vCJD cases still alive: 7

Total
-----

Number of definite or probable vCJD (dead and alive): 157

(The next table will be published on Mon 1 Sep 2005.)

--
ProMED-mail

[Since the previous monthly statistics were
released on Mon 4 Jul 2005, the total number of
deaths from definite or probable vCJD remains
unchanged at 150, but the number of probable vCJD
cases still alive has increased by one and is now
7. Therefore, the overall total number of
definite or probable vCJD cases (dead and alive)
has increased by one and becomes 157.

These data are still consistent with the view
that the vCJD outbreak in the UK is now in
decline. The number of deaths due to definite or
probable vCJD in the UK during the 1st 7 months
of 2005 is 2. The peak number of deaths was 28 in
the year 2000, followed by 20 in 2001, 17 in
2002, 18 in 2003, and 9 in 2004.

As of 29 Jul 2005, so far in the UK for the year
2005, there have been 74 referrals of suspected
CJD, and there have been 24 deaths from sporadic
CJC, one from GSS (Gerstmann-Straussler-Scheinker
syndrome), one from familial CJD, one from
iatrogenic CJD and 2 from vCJD. Data for years
since 1990 can be accessed at

- Mod.CP]

******
[2] UK - warning to blood donors
Date: Wed 20 Jul 2005
From: ProMED-mail
Source: BBC News online, Wed 20 Jul 2005 [edited]


100 Blood Donors Warned of vCJD Risk
-------------------------------------------
All gave blood to 3 people in 1993/4 who have
since died from variant Creutzfeldt-Jakob disease
(vCJD), the human form of bovine spongiform
encephalopathy (BSE) or mad cow disease.
Precautions were brought in during 1999, when it
became apparent that there was a potential for
the prion disease to be transmitted through donor
blood. The Department of Health has asked the 100
donors to notify their doctors so that extra
precautions can be taken if they have surgery or
other invasive care. They are also being asked
not to donate any more blood, tissue or organs.
The department said the move was a precautionary
measure.

It is not known whether the source of vCJD in the
3 patients who died was related to the blood that
they received or to BSE-infected meat that they
ate. Back in September, the government identified
17 people who received blood transfusions from
people who went on to develop vCJD and sent out
6000 letters to others informing them of the
potential risk. Since 1997, all cases of vCJD
that are reported to the National CJD
Surveillance Unit and diagnosed as having
"probable" vCJD are passed on to the National
Blood Service which searches its blood donor
records. If the patient has given blood,
subsequently any stocks of that blood are
immediately destroyed.

White blood cells, which it is thought may carry
the greatest risk of transmitting the disease,
have been removed from all blood used for
transfusion since 1999. And blood products have
been prepared from plasma imported from the US
since 1998. There is no test for the brain
wasting disease, so those at risk have no way of
knowing whether they have vCJD.

Chief Medical Officer Sir Liam Donaldson said:
"When a recipient of a blood transfusion goes on
to develop vCJD, we have to consider the
possibility that the infection could have been
passed on through the transfusion. "Until a
reliable blood screening test becomes available,
it is sensible to proceed with highly
precautionary measures such as this to rule out
any possibility of onward transmission of the
disease." Dr. Angela Robinson from the National
Blood Service said: "This notification exercise
will affect in the order of 100 donors. If you
have donated blood in the last 5 years and are
not contacted shortly, you can be assured that
you are not involved in this new safety measure
and need to take no further action. For those
people who are involved, this information may be
difficult to absorb. That is why we have set up
the National Blood Service helpline and are
working with their doctors and other clinicians
to ensure that they have the information and
support they need." She urged the public to
continue donating blood, saying that the NHS
depended on this continued commitment in order to
be able to save lives.

--
ProMED-mail

******
[3] UK - warning to blood donors
Date: Thu 21 Jul 2005
From: ProMED-mail
Source: Eurosurveillance Weekly, Surveillance
report, Volume 10, Issue 7, Thu 21 Jul 2005
[edited]


UK Blood Donors Identified As At Increased Risk
of vCJD Are To Be Notified of Their Status
-----------------------------------------------
England's Department of Health has announced the
beginning of notification of a group of
individuals who are newly identified as at
increased risk of variant Creutzfeldt-Jakob
disease (vCJD) in the United Kingdom (UK) (1,2).
These are people who have donated blood that was
transfused to patients who subsequently developed
vCJD. This currently concerns around 100 donors
to 3 vCJD cases.

vCJD infection has been observed in 2 recipients
of blood transfusions from donors who later
developed vCJD (3,4). One of these recipients did
not develop vCJD and died of causes unrelated to
the disease. Although other exposures, including,
most notably, dietary exposure to BSE (bovine
spongiform encephalopathy), cannot be excluded as
the source of these patients' infections, it is
considered highly probable that these 2 patients
were infected by blood transfusion. These reports
added to previous evidence of vCJD infectivity in
blood obtained from experiments in animals and
led to the conclusion that transfusion should be
considered a possible route of vCJD transmission
in humans.

Over 2 million blood donations are collected each
year in the UK by the blood services, and over
half a million patients receive transfusions
annually. Of the 150 people who have died from
vCJD in the UK to 1 July 2005 (5), only 4 have
been confirmed as having received blood
transfusions that may be associated with their
subsequent development of vCJD. (For 2 other
cases, symptoms developed before or very shortly
after transfusion, and therefore transfusion is
not considered a possible source of their
infections.) For one of these cases, the probable
source of infection has already been identified,
as one of the donors went on to develop vCJD. For
the remaining 3 cases, transfusion remains a
possible source of the recipients' infection.

A risk assessment by the Department of Health
looked at the probability of donors to vCJD cases
being the source of a recipient's infection and,
therefore, the probability that the donors
themselves are infected (6). The United Kingdom
CJD Incidents Panel (7) considered this risk
assessment and recommended that such donors
should be considered as potentially at-risk of
vCJD for public health purposes' unless the
probability of being infected with vCJD (as
implied by donation to a vCJD case and estimated
with precautionary or worst case assumptions)
falls clearly below one percent.

Unless there is evidence to the contrary, the
assumptions for this calculation are: that an
infected donation would certainly infect the
recipient (the worst case assumption); that there
is no way of distinguishing between the
contributing donors (and recipient) in terms of
risk of primary vCJD infection (e.g., that all
had been resident in the UK during the BSE
outbreak), and that there is no other significant
alternative infection route for the recipient,
such as having been operated on with instruments
previously used for healthcare interventions on a
patient with vCJD.

These individuals are being informed that they
are "potentially at-risk of vCJD for public
health purposes" so that special public health
precautions can be taken to reduce the risk of
person-to-person transmission of vCJD during
their healthcare. Specifically, these are: not to
donate blood, organs or other tissues, and to
inform their healthcare providers of their
"at-risk" status in order that infection control
guidance (8) can be implemented for the
instruments used in certain invasive healthcare
procedures (and so that certain invasive
healthcare procedures that have already been
carried out on them can be considered by the CJD
Incidents Panel).

The 100 or so individuals involved are being
informed by the UK Blood Services. Their general
medical practitioners are being briefed by the
Health Protection Agency and Health Protection
Scotland so that they can provide further
information and support to their patients, and
assist with implementation of the recommended
public health precautions, as required. Where
past invasive healthcare procedures have been
conducted on these individuals, and potentially
contaminated instruments may be a risk for other
patients, local health protection staff are asked
to consult the CJD Incidents Panel for advice
about whether any actions should be taken.

Since its establishment in 2000, the CJD
Incidents Panel has issued advice relating to
several groups of patients identified as at
increased risk of CJD. Other groups of patients
who are considered to be potentially at-risk of
vCJD for public health purposes include: certain
patients who have been operated on with
instruments previously used for healthcare
interventions on a patient with vCJD; recipients
of blood from donors who later developed vCJD,
and patients who have been treated with plasma
products that may have been contaminated with
vCJD infection. This new notification of donors
to vCJD cases is a further precautionary measure
to reduce the possible risk of secondary
transmission of vCJD in the UK. Further
information about this notification can be found
at
.

[Byline: Kate Soldan .
Emerging Infections and Zoonoses Department,
Health Protection Agency Centre for Infections,
London, United Kingdom. This article has been
adapted by the author from reference 1]

References
----------

(1) PA. New group of individuals notified of
increased risk of vCJD. CDR Weekly 2005; 15(29):
news.

(2) Notification exercise begins to reduce risk
of vCJD transmission. Department of Health, press
release 2005/0256, 20 Jul 2005.

(3) Llewelyn CA, Hewitt PE, Knight RSG, Amar K,
Cousens S, Mackenzie J, et al. Possible
transmission of variant CJD disease by blood
transfusion. Lancet 2004; 363;417-421.

(4) Peden AH, Head MW, Ritchie DL, Bell JE,
Ironside JW. Preclinical vCJD after blood
transfusion in a PRNP codon 129 heterozygous
patient. Lancet 2004; 364;527-529.

(5) CJD Statistics. Numbers of deaths of definite
and probable vCJD cases in the UK, reported to
the CJD surveillance unit in Edinburgh up to 1
Jul 2005. The National Creutzfeldt-Jakob Disease
Surveillance Unit website, updated 4 Jul 2005.

(6) Standards and Quality Analytical Team
(Economics, Statistics and Operational Research),
Department of Health. Assessing the Implications
for Blood Donors if Recipients are infected with
vCJD. London; Department of Health; 2004, with
new preface July 2005.

(7) The CJD Incidents Panel

is an expert committee established on behalf of
the UK Chief Medical Officers in 2000.

(8) Transmissible spongiform encephalopathy
agents: safe working and the prevention of
infection. Guidance from the Advisory Committee
on Dangerous Pathogens and the Spongiform
Encephalopathy Advisory Committee. Department of
Health website, June 2003, updated 20 Jul 2005.

--
ProMED-mail

******
[4] Spain - 1st (suspected) vCJD case
Date: Fri 29 Jul 2005
From: P. Nart Penalver
Source: ABC, Spain, Fri 29 Jul 2005 [translated by P. Nart Penalver, edited]


Spain: 1st [Probable] Case of Variant Creutzfeldt-Jakob Disease Reported
-----------------------------------------------
The Ministry of Health confirmed today [Fri 29
Jul 2005] the 1st death in Spain of a person by
variant Creutzfeldt-Jakob disease. According to
the Ministry, the deceased patient was a young
woman 26 years of age, who could have been
infected between 1994 and 1995. The young woman
passed away on 10 Jul 2005 in the Foundation
Alcorcon, Hospital of Madrid. Forensic samples
will be sent for diagnosis confirmation to the
vCJD Reference Centre in Edinburgh, Scotland, and
results are expected in the next 10 days.

The Minister of Health, Elena Salgado, sent a
message of condolence and affirmed that there is
no risk derived from meat consumption in Spain,
since this is considered to be an isolated case.

--
P. Nart Penalver

******
[5] Spain - 1st (suspected) vCJD case
Date: Fri 29 Jul 2005
From: Mary Marshall
Source: Reuters AlertNet, Fri 29 Jul 2005 [edited]


Spain: 1st Probable Death from Mad Cow Disease (vCJD)
-----------------------------------------------
Spain reported the 1st probable death from the
human variant of mad cow disease [variant
Creutzfeldt-Jakob disease] on Friday [29 Jul
2005], a 26-year-old woman who was probably
infected before the mad cow disease scare of 2000
led to strict controls. Spain's Health Ministry
said it believed the death was caused by
Creutzfeldt-Jakob disease (vCJD), based on tests
carried out at a Madrid hospital, and that it had
sent samples to experts in Edinburgh for
confirmation.

The victim most likely had eaten animal products
rich in nerve tissue, while the animal itself had
consumed contaminated feed. The incubation period
in this case was between 5 and 10 years, the
Ministry added. "That means that infection
probably occurred before the exhaustive control
measures established by the government were put
into place," the statement said.

The ministry said controls aimed at stamping out
mad cow disease were established in accordance
with European Union guidelines and guaranteed
that meat consumed in Spain was safe. Spain has
reported 567 cases of bovine spongiform
encephalopathy (BSE), the animal variant of the
disease, from 2000.

Europe's outbreaks of BSE caused panic in the
1980s and 1990s, with 184 000 cases registered in
Britain by 2004. More than 100 people have died,
mostly in Britain, from vCJD after eating tainted
meat. BSE is caused by feeding cattle with
infected parts of other cattle. The EU banned
animal parts from animal feed and also tightened
food safety laws to limit what parts of cattle
can enter the food chain.

--
ProMED-mail

[The number of definite or probable vCJD cases in
the UK (see above) is now 157, followed by France
with 13, Ireland 2, and Italy, the Netherlands,
Portugal and Spain with single cases. Single
cases have been confirmed also in Canada,
Ireland, Japan and the USA involving patients
with periods of residence in the UK and who are
presumed to have contracted infection in the UK.
The Japanese case is exceptional in that the
patient may have spent less than one month in the
UK.

In addition, the US National Prion Disease
Pathology Surveillance Center confirmed a vCJD
diagnosis by analyzing a brain biopsy sample from
a 33-year-old Saudi man admitted to a hospital in
Saudi Arabia. Although detailed information on
this patient was not available, he may have
visited the United Kingdom, if at all, only for
several days. Thus, the patient may have
contracted the disease in Saudi Arabia after
eating BSE-contaminated cattle products imported
from the United Kingdom (see: Belay et al., in
Emerging Infectious Diseases, Vol. 11, No. 9,
September 2005
.

The occurrence of the 1st suspected human case of
vCJD in Spain is not unexpected, since the risk
of contracting vCJD appears to be linked to the
amount of bovine meat consumed or extent of
exposure to bovine products. According to the
latest figure compiled by the European Union and
the OIE, Spain ranks 5th in the world in terms of
the number of BSE-affected cattle (532), after
France with 946, Portugal with 949, Ireland with
1470 and the UK with 184 138. However, by
contrast, in the current year [2005], Spain, with
42 cases, ranks 2nd after the UK with 126 cases,
followed by Ireland with 29, Portugal with 17 and
France with 2 cases of BSE. - Mod.CP]

[see also:
CJD (new var.) - Portugal: 1st case; France 20050611.1630
CJD (new var.) - Netherlands (02): 1st case 20050423.1135
CJD (new var.) - Netherlands: 1st case 20050422.1118
CJD (new var.) update 2005 (07) 20050703.1889
CJD (new var.) update 2005 (06) 20050607.1584
CJD (new var.) update 2005 (05) 20050505.1243
CJD (new var.) update 2005 (04) 20050405.0982
CJD (new var.) update 2005 (03) 20050308.0687
CJD (new var.) update 2005 (02) 20050211.0467
CJD (new var.) - UK: update 2005 (01) 20050111.0095
2004
----
CJD, genetic susceptibility 20041112.3064
CJD (new var.) - UK: update 2004 (14) 20041206.3242
CJD (new var.) - UK: update 2004 (13) 20041103.2977
CJD (new var.) - UK: update 2004 (12) 20041023.2871
CJD (new var.) - UK: update 2004 (11) 20041008.2758
CJD (new var.) - UK: update 2004 (10) 20040909.2518
CJD (new var.) - UK: update 2004 (09) 20040809.2199
CJD (new var.) - UK: update 2004 (08) 20040806.2150
CJD (new var.) - UK: update 2004 (07) 20040706.1807
CJD (new var.) - UK: update 2004 (06) 20040608.1535
CJD (new var.) - UK: update 2004 (05) 20040510.1262
CJD (new var.) - UK: update 2004 (04) 20040406.0937
CJD (new var.) - UK: update 2004 (03) 20040314.0713
CJD (new var.) - UK: update 2004 (02) 20040202.0400
CJD (new var.) - UK: update 2004 (01) 20040106.0064
CJD (new var.) - France: 8th case 20041022.2864
CJD (new var.) - France: 9th case 20041123.3138
CJD (new var.), blood supply - UK 20040318.0758
CJD (new var.), carrier frequency study - UK 20040521.1365
2003
----
CJD (new var.) - UK: update 2003 (13) 20031216.3072
CJD (new var.) - New Zealand: suspected (04) 20030817.2057
CJD (new var.) - Italy (05): death 20030809.1969
CJD (new var.) - New Zealand: suspected 20030807.1941
CJD (new var.) - Czech Republic: suspected 20030711.1707
CJD (new var.) - Spain (Madrid): suspected 20030208.0333
CJD (new var.) - UK: update 2003 (01) 20030108.0057
2002
----
CJD (new var.) - UK: update Dec 2002 20021207.5997
CJD, possible association with BSE 20021129.5921
CJD (new var), susp. case - Italy (Sicily) (04):conf 20020927.5418
CJD (new var.) - Canada (SK) ex UK (02) 20020809.5010
CJD (new var.), suspected - USA (FL) ex UK 20020419.3989
CJD (new var.) - France: sixth case 20020418.3983
CJD (new var.) - China (Hong Kong): confirmed 20020222.3604
CJD (new var.) - UK: update Jan 2002 20020111.3223
2001
----
CJD (new var.), incidence & trends - UK (02) 20011124.2875
CJD (new var.), incidence & trends - UK 20011115.2816
CJD (new var.) - UK: reassessment 20011029.2671
CJD (new var.) - UK: update Oct 2001 20011005.2419
CJD (new var.) - UK: regional variation (02) 20010907.2145
CJD (new var.) - UK: update Sep 2001 20010906.2134
CJD (new var.) - UK: update Aug 2001 20010808.1872
CJD (new var.) - UK: 9th Annual Report 20010628.1231
CJD (new var.) - UK: update June 2001 20010622.1188
CJD (new var.) - UK: update 3 Jan 2001 20010104.0025
1999
----
CJD (new var.), human - Ireland 19990715.1192]
...................cp/msp/lm

*##########################################################*
************************************************************
ProMED-mail makes every effort to verify the reports that
are posted, but the accuracy and completeness of the
information, and of any statements or opinions based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by ProMED-mail. ISID
and its associated service providers shall not be held
responsible for errors or omissions or held liable for any
damages incurred as a result of use or reliance upon posted
or archived material.
************************************************************
Visit ProMED-mail's web site at .
Send all items for posting to: promed@promedmail.org
(NOT to an individual moderator). If you do not give your
full name and affiliation, it may not be posted. Send
commands to subscribe/unsubscribe, get archives, help,
etc. to: majordomo@promedmail.org. For assistance from a
human being send mail to: owner-promed@promedmail.org.
############################################################
############################################################

USA HUMAN/ANIMAL TSE SURVEILLANCE $$$$$$ DREAM ON $$$$$$$$
TSS



Follow Ups:



Post a Followup

Name:
E-mail: (optional)
Subject:

Comments:

Optional Link URL:
Link Title:
Optional Image URL: